# Nxera to receive US$22.5 million in milestone payments from Neurocrine.

*biotech · news · 2026-04-12 · The Manila Times*

## Key points

- Neurocrine has begun dosing patients in a Phase 2 clinical trial of NBI-1117570 for schizophrenia.
- Nxera will receive US$22.5 million in milestone payments from Neurocrine, recognized in Q1 FY2026.
- NBI-1117570 is the second NxWave-designed muscarinic agonist in Neurocrine’s pipeline to reach Phase 2.
- The Phase 2 trial will enroll approximately 120 in-patient adults and use PANSS score as the primary endpoint.

**Companies:** Neurocrine Biosciences Inc., Nxera Pharma Co., Ltd.
**Countries:** Japan, United Kingdom, Switzerland, South Korea, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/13/tmt-newswire/globenewswire/nxera-pharmas-partner-neurocrine-biosciences-doses-first-patient-in-phase-2-trial-of-nbi-1117570-for-adults-with-schizophrenia/2318708)

---

Canonical: https://newsio.io/n/47cc2b09-4809-4b18-ba97-f151ac7aa42c/nxera-to-receive-us22-5-million-in-milestone-payments-from-neurocrine-nbi-111757
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works